Natalizumab: bench to bedside and beyond.

  title={Natalizumab: bench to bedside and beyond.},
  author={Richard A. Rudick and Chris Polman and David Clifford and David Miller and Lawrence Steinman},
  journal={JAMA neurology},
  volume={70 2},
Natalizumab has been available as a multiple sclerosis treatment for more than 5 years in Europe and the United States. Natalizumab was granted approval by the US Food and Drug Administration in 2004, only 12 years after its molecular target was cloned. Shortly after initial approval, natalizumab use was suspended pending a safety review when several natalizumab recipients were diagnosed as having progressive multifocal leukoencephalopathy. After the safety review, natalizumab was reintroduced… CONTINUE READING
44 Citations
72 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 44 extracted citations


Publications referenced by this paper.
Showing 1-10 of 72 references

Similar Papers

Loading similar papers…